Dallas, Texas 01/21/2014 (FINANCIALSTRENDS) – Northwest Biotherapeutics, Inc (NASDAQ:NWBO) is a biotechnology company with its core body of manufacturing and developing immunotherapy products, used in the treatment of cancer. In the recent years, these products of the company are regarded as industry standards over other forms of cancer treatments such as chemotherapy.
Northwest Biotherapeutics, Inc NASDAQ:NWBO) range of technology introduce an alternative for patients to explore so that they are no longer to be bothered with the side effects of toxic treatments. For one chemotherapies are known to cause loss of hair as well as overall weakness to the intense radiation the body suffers from during the process.
Northwest Biotherapeutics, Inc (NASDAQ:NWBO) has a market cap of $175.41 million and volume of 863,287.The shares have seen a 52 week high of 6.89 and 52 week of $ 3.00. The EPS for the company is negative at -3.72.
Northwest Biotherapeutics, Inc (NASDAQ:NWBO) share prices have seen a fall in trading by over 7%. The fall in prices was due to a disruptive article in TheStreet. Analysts’ review of the products in terms of performance led to the drastic fall in the prices. The prediction was that the ICT-107 would also see a fall in the dendritic cancer vaccines. The prediction was based on the fact that the vaccine that Northwest Biotherapeutics, Inc (NASDAQ:NWBO) provides could not overcome the powerful initial stage aggressiveness typical of cancer. As cancer is known to overpower immune systems of the person it attacks, the incapability of the vaccine in not being able to control the penetration is what triggered the article. This is turn, kept the investors away leading to the overall slide in the prices of the stock. The basis of the article was the data for DCVXa was not accurate and it actually misled follow-up. The results of the early studies were not fail-proof, as analysts now feel there was considerable caution exercised in choosing the over 20 brain cancer patients.